Final extension for AsiaPharm takeover set for May 22
MBK Partners stands firm on its takeover offer which, as of April 30, had been accepted by 77.19% of AsiaPharmÆs shareholders. Templeton remains opposed to the deal.
Private equity firm MBK PartnersÆ takeover offer for Singapore-listed drug company AsiaPharm Group has been extended to May 22, according to ABN Amro Bank, which is advising MBK on the deal.MBK Partners has stood firm on the S$0.725 ($0.53) per share offer price of Lu Ye Pharmaceutical Investment, which it controls, in a deal valued at S$357.4 million ($262.6 million). The offer had been accepted by 77.19% of AsiaPharmÆs shareholders as of April 30. This includes AsiaPharm executivesÆ…
Sign In to Your Account
Access Exclusive AsianInvestor Content!
Please sign in to your subscription to unlock full access to our premium AI resources.
Free Registration & 7-Day Trial
Register now to enjoy a 7-day free trial—no registration fees required. Click the link to get started.
Note: This free trial is a one-time offer.
¬ Haymarket Media Limited. All rights reserved.